NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases
-
By
-
Jun Zhou
-
Ruohao Yang
-
Wanyu Zhu
-
Zhilin He
-
Yueke Ma
-
Zhiwei Feng
-
Lili Yu
-
May 29, 2026
-
Clinical Scorecard: Inflammasome Pathways Involving NLR: Crucial Targets for Understanding and Treating Metabolic Disorders
At a Glance
| Category | Detail |
|---|
| Condition | Metabolic Disorders |
| Key Mechanisms | NLR inflammasome activation, chronic low-grade inflammation, metabolic dysfunction |
| Target Population | Individuals with obesity, type 2 diabetes mellitus (T2DM), atherosclerosis, and metabolic dysfunction-associated steatotic liver disease (MASLD) |
| Care Setting | Clinical and research settings focusing on metabolic disease intervention |
Key Highlights
- NLR inflammasomes play a critical role in linking metabolic dysfunction and chronic inflammation.
- NLRP3, NLRP1, NLRP6, NLRC5, and NLRP12 are implicated in various metabolic disorders.
- Chronic low-grade inflammation is a central driver of metabolic diseases.
- Therapeutic strategies include small-molecule inhibitors and cytokine blockade.
- Gut microbiota dysbiosis exacerbates systemic low-grade inflammation.
Guideline-Based Recommendations
Diagnosis
- Identify metabolic disorders through clinical assessment and biomarkers of inflammation.
Management
- Consider targeting NLR inflammasome components for therapeutic intervention.
Monitoring & Follow-up
- Monitor inflammatory cytokine levels and metabolic parameters in affected individuals.
Risks
- Chronic inflammation may lead to insulin resistance and other metabolic complications.
Patient & Prescribing Data
Patients with obesity, T2DM, atherosclerosis, and MASLD.
Potential treatments include inhibitors of NLRP3 and other inflammasome components.
Clinical Best Practices
- Integrate findings from in vitro studies, animal models, and human data for therapeutic strategies.
- Evaluate the role of gut microbiota in metabolic inflammation.
Related Resources & Content
